HB0034

Phase 2Small molecule

SShanghai Huaota Biopharmaceutical Co., Ltd.

HB0034 is one of 11 small molecule programs targeting Generalized Pustular Psoriasis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Generalized Pustular PsoriasisActive, not recruiting

Generalized Pustular PsoriasisPhase 2

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Generalized Pustular Psoriasis

#DrugCompanyPhaseTrials

Taltz

Eli Lilly

Approved

1 2

Spevigo

Boehringer Ingelheim

Approved

7 3

Tremfya

Johnson & Johnson

Phase 3

1 4

Skyrizi

AbbVie

Phase 3

1 5

Humira

CCelltrion

Phase 3

1 6

TAK-279

Takeda

Phase 3

1 7

JNJ-77242113

Johnson & Johnson

Phase 3

1 8

Imsidolimab

VVanda Pharmaceuticals

Phase 2

2 9

Cosentyx

Novartis

Preclinical

1 10

Stelara

Johnson & Johnson

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Generalized Pustular Psoriasis3 trials

Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis

Recruiting·SShanghai Huaota Biopharmaceutical Co., Ltd.·Phase 2/3·NCT06477536·33 enrolled

HB0034 in Patients With Generalized Pustular Psoriasis (GPP)

Completed·SShanghai Huaota Biopharmaceutical Co., Ltd.·Phase 1·NCT05512598·9 enrolled

Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)

Recruiting·SShanghai Huaota Biopharmaceutical Co., Ltd.·Phase 2·NCT06231381·33 enrolled

Adult2 trials

A Study to Evaluate HB0034 in Healthy Adult Participants

Completed·SShanghai Huaota Biopharmaceutical Co., Ltd.·Phase 1·NCT05064345·56 enrolled

A Study to Evaluate HB0034 in Healthy Chinese Adult Participants

Recruiting·SShanghai Huaota Biopharmaceutical Co., Ltd.·Phase 1·NCT06716151·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for HB0034. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HB0034 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HB0034. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Huaota Biopharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShanghai Huaota Biopharmaceutical Co., Ltd.

HB0034

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Generalized Pustular Psoriasis3 trials

Adult2 trials

References

Drug Info

Quick Facts

Related News